Publications

  1. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology. 2003; 144(5):1656-63.
  2. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology. 2004 Jun; 145(6):2941-9.
  3. Liao X, Tang S, Griebling T, Thrasher JB, and Li B. siRNA-mediated androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther, 2005, 4(4):505-15.
  4. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther. 2003 Nov; 2(11):1215-22.
  5. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005; 4(9):1311-9. 
  6. Sun A, Tawfik O, Geyrad B, Thrasher JB, Hoesije, S, Li C and Li B. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. The Prostate, 2007, 67(2):203-13.
  7. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, Xu P, Spencer D. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis. 2007, 28(3):572-83.
  8. Sun A, Shanmugam I, Youn Y, Song J, Terranova P, Thrasher JB, and Li B. Lithium suppress cell proliferation and E2F-mediated gene expression by disrupting E2F-DNA interaction in prostate cancer cells. The Prostate, 2007, 67(9):976-988. PMID: 17440966.
  9. Shanmugam I, Cheng G, Terranova P, Thrasher JB, Thomas CP, and Li B. Serum/Glucocorticoid- induced Protein Kinase-1 Facilitates Androgen Receptor-dependent Cell Survival. Cell Death and Differentiation, 2007, 14(2):2085-2094. PMID: 17932503.
  10. Sun A, Tang J, Hong Y, Song J, Terranova P, Thrasher JB, Svojanovsky S, Wang H and Li B. Androgen Receptor-dependent Regulation of Bcl-xL Expression: Implication in Prostate Cancer Progression. The Prostate, 2008, 68(4):453-461. PMID: 18196538.
  11. Zhu Q, Tang J, Youn H, Tawfik O, Terranova P, Du J, Raynal P, Thrasher JB, and Li B. Phosphoinositide 3-OH kinase p110b is essential for androgen receptor transactivation and tumor growth in prostate cancer. Oncogene, 2008 27(33):4569-79. PMC2597686.
  12. Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, Christenson L, Li B, Zhang J, Jackson PD, Faber P, Brunden KR, Harrington JJ, Quarles LD. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One. 2008; 3(12):e3858.
  13. Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, Mukhtar H. Lupeol Inhibits Proliferation of Human Prostate Cancer Cells by Targeting ß-catenin Signaling. Carcinogenesis, 2009; 30(5):808-817. PMCID: PMC2722146.
  14. Li H, Ruan G, Li Z, Liu Z, Zheng X, Zheng H, Cheng G, Li B, Zhan M. The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells. J Exp Clin Cancer Res. 2009 Jul 14; 28:100.
  15. Sun A, Tang J, Terranova PF, Zhang X, Thrasher JB, Li B. AAV-delivered short-hairpin RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: A pre-clinical study. Int J Cancer. 2010 Feb 1; 126(3):764-74. PMID: 19642108. 
  16. Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, Thrasher JB, Wang HG, Li B. GSK-3b promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci. 2010 Feb 16. 123(6)861-870. PMC2831760.
  17. Xin Gao, Jun Pang, Liao-Yuan Li, Wei-Peng Liu, Jin-Ming Di, Qi-Peng Sun, You-Qiang Fang, Xiao-Peng Liu, Xiao-Yong Pu, Dan He, Ming-Tao Li, Zu-Lan Su, Li B. Expression profiling identifies new function of collapsin response mediator protein-4 as a metastasis-suppressor in prostate cancer. Oncogene, 2010, June 14, 29:4555-4566.
  18. Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care. 2010 Jul; 33(7):1618-24.
  19. Liu J, Youn H, Yang J, Du N, Liu J, Liu H, Li B. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. Prostate. 2011 Sep; 71(12):1276-86. doi: 10.1002/pros.21345
  20. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011 Jun 1; 71(8):835-45. PMID:21456066
  21. Tai W, Shukla RS, Qin B, Li B, Cheng K. Development of a Peptide-Drug Conjugate for Prostate Cancer Therapy. Mol Pharm. 2011 6;8(3):901-12. PMID:21510670.
  22. Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2012 Apr; 23(4):437-44. doi: 10.1097/CAD.0b013e32834fd01f. PMID:22205155
  23. Cai Z, Li B, Li K, Zhao B. Down-Regulation of Amyloid-β Through AMPK Activation by Inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 Cells. J Alzheimers Dis. 2012 Jan 1;29(1):89-98.
  24. Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012 Jan 30. doi: 10.1002/pros. 22493. [Epub ahead of print].
  25. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, Forrest ML. Prodrug Strategy for PSMA-Targeted Delivery of TGX-221 to Prostate Cancer Cells. Mol Pharm. 2012 Jun 4;9(6):1705-16. Epub 2012 May 1.
  26. Yang J, Xie SX, Huang Y, Ling M, Liu J, Ran Y, Wang Y, Thrasher JB, Berkland C, Li B. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond). 2012 May 14. [Epub ahead of print] PMID:22583574.

Meeting Abstracts (as the 1st author)

 

  1. Li B and Liao X.
    Androgen induction of MMP-2 expression in prostate cancer.
    September 2002; American Association for Cancer Research (AACR)
    Specific Conference on MMPs, Hilton Head Island, SC.
  2. Li B and Thrasher JB.
    GSK‑3b activity is required for androgen receptor transactivation in prostate cancer.
    April 2003. The American Urological Association (AUA), Annual Meeting, Chicago, IL.
  3. Liao X and Li B.
    siRNA-mediated AR silencing leads to apoptotic cell death in prostate cancer cells.
    March 2004, the American Association for Cancer Research (AACR) annual meeting. Orlando, FL
  4. Li B and Tang S.
    14-3-3 proteins in prostate cancer.
    Feb 2004, The first Gordon conference on [the Biology of 14-3-3]. Ventura, CA.
  5. Li B and Liao X.
    Bcl-xL as a downstream effecter in AR-mediated survival.
    October 2004, The 11th Annual Scientific Retreat, Prostate Cancer Foundation, Reno, NV
  6. Li B and Liao X.
    AR-mediated regulation of Bcl-xL expression in prostate cancer.
    Feb 2005, The Keystone Symposium of Hormonal Regulation of Tumorigenesis. Monterey, CA.
  7. Li B and Thrasher JB.
    Androgen Receptor-mediated Bcl-xL expression in prostate cancer.
    May 2005, The American Urological Association (AUA) annual meeting, San Antonio, TX.
  8. McIntosh J, Thrasher JB and Li B.
    Galpha12 is required for androgen-induced gene expression in prostate cancer.
    May 2006, the American Urological Association (AUA) annual Meeting, Atlanta, GA.
  9. Youn H, Thrasher JB  and Li B.
    G-proteins in modulation of AR transactivation.
    October 2006, The 85th Annual Meeting, South Central Section,
    American Urological Association (AUA), Santa Fe, NM
  10. Li B and Shanmugam I.
    SGK-1 facilitates AR-dependent survival in prostate cancer.
    November 2006, American Association for Cancer Research (AACR)
    Special Conference on “Inovations in Prostate Cancer Research”,
    San Francisco, CA
  11. Li B and Tang S.
    Androgen Receptor siRNA eliminates prostate cancer in vivo
    Mar 2007, “Molecular Targets for Cancer (X3)”, Keystone Symposium Series,
    Whistler Resort, Whistler, British Columbia, Canada
  12. Li B and Sun A.
    Systemic delivery of AAV-based AR siRNA constructs eradicates prostate cancer in nude mice.
    September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
  13. Li B and Tang S.
    Conditional Akt activation promotes androgen-independent progression of prostate cancer.
    September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
  14. Tang J, Hong Y, Thrasher JB and Li B.
    AAV-based AR siRNA constructs eradicate prostate cancer in nude mice.
    April 2008, American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA
  15. Yang J, Tang J and Li B.
    GSK-3 modulates Autophagy after growth factor depletion.
    April 2008, American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA
  16. Davis J, Thrasher JB and Li B.
    PI3K p110b is required for androgen receptor signaling and tumor progression in prostate cancers.
    May 2008, American Urological Association (AUA) Annual Meeting, Orlando, FL
  17. Benyi Li
    PI3K pathway in AR signaling and Prostate Cancer Progression
    August 2008, The 3rd IDeA Meeting, Washington D.C.,
  18. Benyi Li, Hyewon Youn, Qin Zhu, J. Brantley Thrasher.
    G-protein alpha-modulated PI3K p110beta activation is involved in androgen receptor transactivation in prostate cancers.
    April 2009, American Urological Association (AUA) Annual Meeting, Chicago, IL
  19. Yang J and Benyi Li
    GSK-3-modulated autophagy acts as a switch between necrosis and apoptosis
    April 2009, American Association for Cancer Research (AACR) Annual Meeting, Denver, CO.
  20. Yang J, Shenxue Xie, Cory Berkland and Benyi Li
    Nanoparticle-based delivery of androgen receptor siRNA for prostate cancer intervention.
    2011 IMPaCT Conference Poster Presentation
    Orlando, FL, March 10, 2011
  21. Yiling Huang, Laird Forrest and Benyi Li
    Targeted delivery of nanoparticle encapsulated p110beta specific inhibitor for prostate cancer intervention.
    2011 IMPaCT Conference Poster Presentation
    Orlando, FL, March 10, 2011
  22. Andrew James, Benyi Li, Jeffrey Holzbeierlein
    Natural compound alternol activates apoptosis and autophagy in prostate cancer cells.
    2011 AUA Annual Meeting,
    Washington DC, May 14-18, 2011.

Last modified: Sep 07, 2012
ID=x7279